RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Altimmune, Inc. · Alcohol Liver Disease
Phase 2
Recruiting
100
2026-03
Industry sponsor intelligence
Altimmune, Inc.Clinical Pipeline.
Lead-sponsor view of Altimmune, Inc.'s indexed peptide studies, development phases, active programs, completed work and recent registry changes.
- Total
- 9
- Recruiting
- 1
- Active
- 0
- Completed
- 8
- Results posted
- 0
- Avg enrollment
- 129
Pipeline overview
Programs by phase and activity.
Velocity
Altimmune, Inc. trials by start year
Study start year · indexed snapshot
Development
Trials by phase
9phase labels
Early Phase 10
Phase 15
Phase 24
Phase 30
Phase 40
| Product | Studies | Early / I | Phase II | Phase III | Phase IV | Active |
|---|---|---|---|---|---|---|
| Pemvidutide → | 9 | 5 | 4 | 0 | 0 | 1 |
Active peptide trials
In motion now.
NCT IDStudyPhase / statusEnrollmentUpdated
Completed trials
Finished registry records.
NCT IDStudyPhase / statusEnrollmentUpdated
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Altimmune, Inc. · Alcohol Use Disorder (AUD)
Phase 2
Completed
100
2026-07
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Altimmune, Inc. · Non-Alcoholic Steatohepatitis (NASH)
Phase 2
Completed
212
2026-05
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
Altimmune, Inc. · Obesity · Nonalcoholic Steatohepatitis
Phase 1
Completed
100
2025-06
Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
Altimmune, Inc. · NASH - Nonalcoholic Steatohepatitis
Phase 1
Completed
40
2025-06
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
Altimmune, Inc. · Type 2 Diabetes
Phase 1
Completed
55
2025-06
Efficacy and Safety of ALT-801 in the Treatment of Obesity
Altimmune, Inc. · Obesity/Overweight
Phase 2
Completed
391
2023-11
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
Altimmune, Inc. · Non-Alcoholic Fatty Liver Disease
Phase 1
Completed
95
2023-07
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
Altimmune, Inc. · Non-Alcoholic Fatty Liver Disease
Phase 1
Completed
64
2023-07
Search sponsor records
All Altimmune, Inc. studies.
This page groups studies where Altimmune, Inc. is listed as the lead industry sponsor. Collaborator-only records are not included in the count.
9 matching studies
Last registry update first
Recent updates
Latest registry movement.
NCT06987513RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightJul 31, 2026NCT05989711IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)May 18, 2026NCT07009860RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)Mar 20, 2026NCT04561245ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityJun 24, 2025NCT04972396Pemvidutide (ALT-801) DDI Study in Healthy VolunteersJun 24, 2025NCT05134662ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)Jun 24, 2025NCT05295875Efficacy and Safety of ALT-801 in the Treatment of ObesityNov 29, 2023NCT05006885ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)Jul 27, 2023NCT05292911Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)Jul 27, 2023